PAID Discloses Forbearance on $5.97M of Defaulted Embolx Notes
Paid Inc filed a forbearance and loan modification agreement covering a $5,967,100 default balance owed by medical device firm Embolx, including $687,500 of fresh funding.
Paid Inc filed a forbearance and loan modification agreement covering a $5,967,100 default balance owed by medical device firm Embolx, including $687,500 of fresh funding.
Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.
Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.
Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.
VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.